Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Stem Cell Research

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 336 articles:
HTML format



Single Articles


    March 2024
  1. ESTRAN S, Loschi M, Benachour S, Soldati A, et al
    Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial.
    Bone Marrow Transplant. 2024 Mar 20. doi: 10.1038/s41409-024-02271.
    PubMed     Abstract available


  2. GUIEZE R, Eikema DJ, Koster L, Schetelig J, et al
    Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Mar 19. doi: 10.1038/s41409-024-02256.
    PubMed     Abstract available


  3. YADAV H, Herasevich S, Zhang Z, White BA, et al
    Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study.
    Bone Marrow Transplant. 2024 Mar 16. doi: 10.1038/s41409-024-02265.
    PubMed     Abstract available


  4. ROBIN M, Iacobelli S, Koster L, Passweg J, et al
    Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Mar 15. doi: 10.1038/s41409-024-02269.
    PubMed     Abstract available


  5. FURST S, Bernit E, Legrand F, Granata A, et al
    Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease.
    Bone Marrow Transplant. 2024 Mar 14. doi: 10.1038/s41409-024-02257.
    PubMed     Abstract available


  6. SAUER S, Engelhardt M, Trautmann-Grill K, Kimmich C, et al
    Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany.
    Bone Marrow Transplant. 2024 Mar 14. doi: 10.1038/s41409-024-02208.
    PubMed     Abstract available


  7. MORRIS SL, Thomas BR, Palanicawandar R, Whittaker S, et al
    Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
    Bone Marrow Transplant. 2024 Mar 12. doi: 10.1038/s41409-024-02236.
    PubMed     Abstract available


  8. FRAEBEL J, Park S, Shah R, Prieto-Granada C, et al
    GVHD like skin eruption post-autologous stem cell transplantation.
    Bone Marrow Transplant. 2024 Mar 11. doi: 10.1038/s41409-024-02259.
    PubMed    


  9. FAZIO F, Passucci M, Micozzi J, Di Landro F, et al
    Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.
    Bone Marrow Transplant. 2024 Mar 9. doi: 10.1038/s41409-024-02260.
    PubMed    


  10. DACHY G, Vankeerbergen M, Vanlangendonck N, Straetmans N, et al
    Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Mar 8. doi: 10.1038/s41409-024-02242.
    PubMed    


  11. CHU SC, Hsieh CJ, Li CC, Yang SH, et al
    Long-term follow-up of cancer and catastrophic diseases in hematopoietic stem cell donors: a comprehensive matched cohort study.
    Bone Marrow Transplant. 2024 Mar 7. doi: 10.1038/s41409-024-02204.
    PubMed     Abstract available


  12. SHANG Q, Bai L, Cheng Y, Suo P, et al
    Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia.
    Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02214.
    PubMed     Abstract available


  13. PARK S, Bang SY, Kwag D, Lee JH, et al
    Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.
    Bone Marrow Transplant. 2024 Mar 4. doi: 10.1038/s41409-024-02255.
    PubMed     Abstract available


    February 2024
  14. YANG YM, Guo SJ, Xiao R, Yu XJ, et al
    Prevalence of osteoporosis among patients after stem cell transplantation: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2024 Feb 29. doi: 10.1038/s41409-024-02243.
    PubMed     Abstract available


  15. BACCELLI F, Gottardi F, Muratore E, Leardini D, et al
    Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
    Bone Marrow Transplant. 2024 Feb 24. doi: 10.1038/s41409-024-02252.
    PubMed     Abstract available


  16. FINAZZI MC, Weber A, Pavoni C, Grassi A, et al
    Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Feb 24. doi: 10.1038/s41409-024-02247.
    PubMed     Abstract available


  17. MURRAY A, Linn SM, Yu B, Novitzky-Basso I, et al
    Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease.
    Bone Marrow Transplant. 2024 Feb 24. doi: 10.1038/s41409-024-02249.
    PubMed     Abstract available


  18. PATTIPAKA T, Sarp S, Nakhaei P, Gunes S, et al
    Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program.
    Bone Marrow Transplant. 2024 Feb 15. doi: 10.1038/s41409-024-02207.
    PubMed     Abstract available


  19. MOHAN M, Szabo A, Patwari A, Esselmann J, et al
    Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.
    Bone Marrow Transplant. 2024 Feb 15. doi: 10.1038/s41409-024-02233.
    PubMed     Abstract available


  20. NAKAYA Y, Nakamae H, Nishikubo M, Kondo E, et al
    Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02229.
    PubMed     Abstract available


  21. MALEK AE, Al-Juhaishi T, Milton DR, Ramdial JL, et al
    Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02238.
    PubMed    


  22. MOSER O, Ngoya M, Galimard JE, Dalissier A, et al
    Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study.
    Bone Marrow Transplant. 2024 Feb 8. doi: 10.1038/s41409-024-02226.
    PubMed     Abstract available


  23. PAVIGLIANITI A, Ngoya M, Pena M, Boumendil A, et al
    Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor.
    Bone Marrow Transplant. 2024 Feb 8. doi: 10.1038/s41409-024-02225.
    PubMed     Abstract available


  24. MEISSNER B, Lang P, Bader P, Hoenig M, et al
    Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression.
    Bone Marrow Transplant. 2024 Feb 7. doi: 10.1038/s41409-024-02219.
    PubMed     Abstract available


  25. AHMADI P, Ghandili S, Jakobs F, Konnopka C, et al
    Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
    Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02228.
    PubMed    


  26. OECHSLER S, Gagelmann N, Wolschke C, Janson D, et al
    Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02220.
    PubMed     Abstract available


  27. ALFARO MOYA T, Salas MQ, Santos Carreira A, Atenafu EG, et al
    Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies.
    Bone Marrow Transplant. 2024 Feb 5. doi: 10.1038/s41409-024-02216.
    PubMed     Abstract available


    January 2024
  28. GALAVERNA F, Baccelli F, Zama D, Tridello G, et al
    Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).
    Bone Marrow Transplant. 2024 Jan 25. doi: 10.1038/s41409-024-02209.
    PubMed     Abstract available


  29. XIAO M, Zhou J, Zhu X, He Y, et al
    A prognostic score system in adult T-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Jan 24. doi: 10.1038/s41409-024-02211.
    PubMed     Abstract available


  30. SALAFIAN K, Mazimba C, Volodin L, Varadarajan I, et al
    The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma.
    Bone Marrow Transplant. 2024 Jan 18. doi: 10.1038/s41409-024-02200.
    PubMed     Abstract available


  31. SHARMA A, Galimard JE, Pryce A, Bhoopalan SV, et al
    Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study.
    Bone Marrow Transplant. 2024 Jan 15. doi: 10.1038/s41409-024-02197.
    PubMed     Abstract available


  32. PAHNKE S, Hagglund H, Larfors G
    Incidence of cardiovascular disease in healthy Swedish peripheral blood stem cell donors - a nationwide study.
    Bone Marrow Transplant. 2024 Jan 11. doi: 10.1038/s41409-023-02196.
    PubMed     Abstract available


  33. ARCURI LJ
    Re: Prophylactic versus preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Bone Marrow Transplant. 2024 Jan 10. doi: 10.1038/s41409-023-02186.
    PubMed    


  34. DE TUTE RM, Cook G, Cairns DA, Brown JM, et al
    Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial.
    Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02164.
    PubMed    


  35. CHHABRA S, Jerkins JH, Monahan K, Szabo A, et al
    Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2024 Jan 4. doi: 10.1038/s41409-023-02178.
    PubMed     Abstract available


    December 2023
  36. ZHANG Y, Guo J, Chen W, Zhao L, et al
    Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation.
    Bone Marrow Transplant. 2023 Dec 26. doi: 10.1038/s41409-023-02185.
    PubMed     Abstract available


  37. ZHANG X, Pang Y, Wei C, Liang D, et al
    Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
    Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
    PubMed    


  38. SUGITA J, Kuroha T, Ishikawa J, Eto T, et al
    Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor.
    Bone Marrow Transplant. 2023 Dec 19. doi: 10.1038/s41409-023-02162.
    PubMed     Abstract available


  39. ITO S, Saito A, Sakurai A, Watanabe K, et al
    Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02161.
    PubMed     Abstract available


  40. JINDAL N, C M, Mathew LJ, Kumbhalwar K, et al
    Fertility outcomes in patients desiring conception following autologous stem cell transplantation for hodgkin lymphoma using LACE conditioning.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02179.
    PubMed    


  41. KATO K, Sugio T, Ikeda T, Yoshitsugu K, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02156.
    PubMed     Abstract available


  42. GABELLI M, Perez-Martinez A, Bueno Sanchez D, Lucchini G, et al
    Abatacept treatment for autoimmune hemolytic anemia occurring post hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Dec 14. doi: 10.1038/s41409-023-02173.
    PubMed    


  43. PUSIC I, Lee C, Veeraputhiran M, Minor C, et al
    Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease.
    Bone Marrow Transplant. 2023 Dec 9. doi: 10.1038/s41409-023-02165.
    PubMed    


  44. GJAERDE LK, Ruutu T, Peczynski C, Boreland W, et al
    The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party.
    Bone Marrow Transplant. 2023 Dec 7. doi: 10.1038/s41409-023-02154.
    PubMed     Abstract available


  45. DUQUE-AFONSO J, Finke J, Ngoya M, Galimard JE, et al
    Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT
    Bone Marrow Transplant. 2023 Dec 2. doi: 10.1038/s41409-023-02150.
    PubMed     Abstract available


    November 2023
  46. MALAGOLA M, Radici V, Farina M, Pellizzeri S, et al
    Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2023 Nov 29. doi: 10.1038/s41409-023-02158.
    PubMed    


  47. HUANG QS, Han TX, Chen Q, Wu J, et al
    Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Nov 27. doi: 10.1038/s41409-023-02151.
    PubMed     Abstract available


  48. MATHIESEN S, Jensen CFS, Byrjalsen A, Aksglaede L, et al
    Microdissection testicular sperm extraction after pediatric allogeneic hematopoietic stem cell transplantation: a case series.
    Bone Marrow Transplant. 2023 Nov 25. doi: 10.1038/s41409-023-02152.
    PubMed    


  49. CAO LQ, Huo WX, Zhang XH, Xu LP, et al
    Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients.
    Bone Marrow Transplant. 2023 Nov 15. doi: 10.1038/s41409-023-02117.
    PubMed     Abstract available


  50. KIM H, Ali R, Short S, Kaunfer S, et al
    AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2023 Nov 7. doi: 10.1038/s41409-023-02136.
    PubMed     Abstract available


  51. CELIK S, Kaynar L, Guven ZT, Atasever Duran K, et al
    The effect of danger-associated molecular patterns on survival in acute graft versus host disease.
    Bone Marrow Transplant. 2023 Nov 7. doi: 10.1038/s41409-023-02145.
    PubMed     Abstract available


  52. PHILIPPEN L, Schub N, Gunther A, Cario G, et al
    Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease.
    Bone Marrow Transplant. 2023 Nov 6. doi: 10.1038/s41409-023-02144.
    PubMed    


  53. PATEL P, Dillon M, Niedzwiecki D, Crowell KA, et al
    High risk of acute pulmonary toxicity with both myeloablative and non-myeloablative total body irradiation-based conditioning for allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2023 Nov 3. doi: 10.1038/s41409-023-02140.
    PubMed    


    October 2023
  54. YANG L, Lai X, Yang T, Lu Y, et al
    Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Bone Marrow Transplant. 2023 Oct 31. doi: 10.1038/s41409-023-02137.
    PubMed     Abstract available


  55. HUANG J, Feng B, Cheng Y, Xu L, et al
    Unmanipulated haploidentical hematopoietic stem cell transplantation for mixed phenotype acute leukemia: a single center study.
    Bone Marrow Transplant. 2023 Oct 31. doi: 10.1038/s41409-023-02141.
    PubMed    


  56. HOLLAENDER N, Glimm E, Gauvin J, Stefanelli T, et al
    A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study.
    Bone Marrow Transplant. 2023 Oct 28. doi: 10.1038/s41409-023-02128.
    PubMed     Abstract available


  57. SHIMOMURA Y, Komukai S, Kitamura T, Sobue T, et al
    Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide.
    Bone Marrow Transplant. 2023 Oct 28. doi: 10.1038/s41409-023-02142.
    PubMed     Abstract available


  58. AYAS M, Al-Hashim F, Siddiqui K, Al-Jefri A, et al
    Hematopoietic stem cell transplantation in patients with Fanconi anemia: a report of late effects and psychosocial adjustment in life.
    Bone Marrow Transplant. 2023 Oct 25. doi: 10.1038/s41409-023-02133.
    PubMed    


  59. MALAGOLA M, Radici V, Farina M, Pellizzeri S, et al
    CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2023 Oct 19. doi: 10.1038/s41409-023-02124.
    PubMed    


  60. GOYAL A, O'Leary D, Foss F
    Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2023 Oct 18. doi: 10.1038/s41409-023-02122.
    PubMed     Abstract available


  61. AL-RAMAHI JS, Shahzad M, Nguyen A, Li K, et al
    Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Oct 13. doi: 10.1038/s41409-023-02125.
    PubMed    


  62. IKEDA DJ, DeFilipp Z, Collier K, Chen YB, et al
    Low incidence of engraftment syndrome following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide.
    Bone Marrow Transplant. 2023 Oct 11. doi: 10.1038/s41409-023-02123.
    PubMed    


  63. KORESAWA-SHIMIZU R, Suzuki R, Uehara Y, Hiramoto N, et al
    Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry.
    Bone Marrow Transplant. 2023 Oct 7. doi: 10.1038/s41409-023-02118.
    PubMed    


    September 2023
  64. SATTY AM, Klein E, Mauguen A, Kunvarjee B, et al
    T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML.
    Bone Marrow Transplant. 2023 Sep 29. doi: 10.1038/s41409-023-02113.
    PubMed     Abstract available


  65. CAO Y, Zhang C, Zhao X, Huang J, et al
    Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China.
    Bone Marrow Transplant. 2023 Sep 20. doi: 10.1038/s41409-023-02106.
    PubMed    


  66. HONG J, Fraebel J, Yang Y, Tkacyk E, et al
    Understanding and treatment of cutaneous graft-versus-host-disease.
    Bone Marrow Transplant. 2023 Sep 20. doi: 10.1038/s41409-023-02109.
    PubMed     Abstract available


  67. HARADA N, Okamura H, Makuuchi Y, Kuno M, et al
    Third HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide for relapsed acute leukemia.
    Bone Marrow Transplant. 2023 Sep 15. doi: 10.1038/s41409-023-02108.
    PubMed    


  68. ALEIXO GFP, Wei W, Chen PH, Gandhi NS, et al
    The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2023 Sep 12. doi: 10.1038/s41409-023-02104.
    PubMed     Abstract available


  69. ZHAO AT, Pirsl F, Steinberg SM, Holtzman NG, et al
    Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease.
    Bone Marrow Transplant. 2023 Sep 8. doi: 10.1038/s41409-023-02097.
    PubMed     Abstract available


  70. FU H, Lv M, Liu H, Sun Y, et al
    Thrombopoietin level predicts the response to avatrombopag treatment for persistent thrombocytopenia after haploidentical haematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Sep 7. doi: 10.1038/s41409-023-02100.
    PubMed     Abstract available


  71. WOREL N, Ljungman P, Verheggen ICM, Hoogenboom JD, et al
    Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Pa
    Bone Marrow Transplant. 2023 Sep 6. doi: 10.1038/s41409-023-02099.
    PubMed     Abstract available


  72. VASWANI PPM, Onozawa M, Hasegawa Y, Ohigashi H, et al
    Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease.
    Bone Marrow Transplant. 2023 Sep 5. doi: 10.1038/s41409-023-02103.
    PubMed    


  73. KNIGHT TE, Ahn KW, Hebert KM, Atshan R, et al
    No impact of CD34(+) cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma.
    Bone Marrow Transplant. 2023 Sep 4. doi: 10.1038/s41409-023-02092.
    PubMed    


  74. NAGLER A, Labopin M, Kroger N, Schroeder T, et al
    The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT.
    Bone Marrow Transplant. 2023 Sep 2. doi: 10.1038/s41409-023-02095.
    PubMed     Abstract available


    August 2023
  75. REY G, Daguenet E, Bonjean P, Devillier R, et al
    Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC.
    Bone Marrow Transplant. 2023 Aug 31. doi: 10.1038/s41409-023-02082.
    PubMed     Abstract available


  76. ZHANG Z, Wieruszewski PM, Hefazi Torghabeh M, Hogan WJ, et al
    Pulmonary function and long-term survival in patients with PERDS after autologous hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Aug 31. doi: 10.1038/s41409-023-02101.
    PubMed    


  77. CHEN J, Labopin M, Pabst T, Zhang X, et al
    Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the globa
    Bone Marrow Transplant. 2023 Aug 28. doi: 10.1038/s41409-023-02070.
    PubMed     Abstract available


  78. WIENER L, Sannes TS, Randall J, Lahijana S, et al
    Psychosocial assessment practices for hematopoietic stem cell transplantation: a national survey study.
    Bone Marrow Transplant. 2023 Aug 26. doi: 10.1038/s41409-023-02087.
    PubMed     Abstract available


  79. BALJEVIC M, Sborov DW
    Understanding risks and refining strategies for thromboembolism prophylaxis in hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2023 Aug 25. doi: 10.1038/s41409-023-02044.
    PubMed    


  80. GJAERDE LK, Peczynski C, Polge E, Kroger N, et al
    Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT.
    Bone Marrow Transplant. 2023 Aug 23. doi: 10.1038/s41409-023-02067.
    PubMed    


  81. DULERY R, Malard F, Brissot E, Banet A, et al
    Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation.
    Bone Marrow Transplant. 2023 Aug 18. doi: 10.1038/s41409-023-02085.
    PubMed     Abstract available


  82. RAGHUNANDAN S, Qayed M, Watkins BK, Graiser M, et al
    Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies.
    Bone Marrow Transplant. 2023 Aug 14. doi: 10.1038/s41409-023-02043.
    PubMed    


  83. RAGHUNANDAN S, Gorfinkel L, Bratrude B, Suessmuth Y, et al
    Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis.
    Bone Marrow Transplant. 2023 Aug 14. doi: 10.1038/s41409-023-02034.
    PubMed    


  84. SANZ J, Labopin M, Pabst T, Versluis J, et al
    Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working P
    Bone Marrow Transplant. 2023 Aug 8. doi: 10.1038/s41409-023-02075.
    PubMed     Abstract available


  85. ANDERSEN S, Xu J, Llewellyn S, Kennedy G, et al
    Nutrition support and clinical outcomes following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2023 Aug 4. doi: 10.1038/s41409-023-02080.
    PubMed     Abstract available


  86. ROSSI M, Szepetowski S, Yakouben K, Paillard C, et al
    Recent results of hematopoietic stem cell transplantation for thalassemia with busulfan-based conditioning regimen in France: improved thalassemia free survival despite frequent mixed chimerism. A retrospective study from the Francophone Society of St
    Bone Marrow Transplant. 2023 Aug 4. doi: 10.1038/s41409-023-02079.
    PubMed    


  87. SCOTT AP, Henden A, Kennedy GA, Tey SK, et al
    PET assessment of acute gastrointestinal graft versus host disease.
    Bone Marrow Transplant. 2023 Aug 3. doi: 10.1038/s41409-023-02038.
    PubMed     Abstract available


  88. EL FAKIH R, Abdulqawi R, Bugnah A, Arabi TZ, et al
    Lung transplantation for pulmonary graft versus host disease: experience from a referral organ transplantation center.
    Bone Marrow Transplant. 2023 Aug 2. doi: 10.1038/s41409-023-02074.
    PubMed    


  89. SANCHEZ IBANEZ J, Bokhorst A, Chandrasekar A, Dominguez-Gil B, et al
    Protection of haematopoietic progenitor cell donors: an updated overview of the European landscape.
    Bone Marrow Transplant. 2023;58:842-848.
    PubMed     Abstract available


    July 2023
  90. LI AA, Yu YY, Gao XM, Zhao H, et al
    Treatment and outcome of second-line therapy for POEMS syndrome after autologous stem cell transplantation.
    Bone Marrow Transplant. 2023 Jul 24. doi: 10.1038/s41409-023-02047.
    PubMed    


  91. BESHENSKY D, Pirsl F, Holtzman NG, Steinberg SM, et al
    Predictors and significance of kidney dysfunction in patients with chronic graft-versus-host disease.
    Bone Marrow Transplant. 2023 Jul 20. doi: 10.1038/s41409-023-02032.
    PubMed     Abstract available


  92. SMITH K, Fathoala D, Anthias C, Easdale S, et al
    Venetoclax-based salvage for management of relapsed acute leukaemia after allogeneic haematopoetic stem cell transplant: durable remissions only seen following consolidation with donor lymphocyte infusion or second transplant.
    Bone Marrow Transplant. 2023 Jul 12. doi: 10.1038/s41409-023-02029.
    PubMed    


  93. SHEN Y, Zhang T, Zhang L, Zhen S, et al
    Allogeneic stem cell transplantation can prolong the survival of patients with NUP98-rearranged acute myeloid leukemia.
    Bone Marrow Transplant. 2023 Jul 7. doi: 10.1038/s41409-023-02030.
    PubMed    


  94. CASIRATI A, Salcedo I, Cereda E, Chabannon C, et al
    The European Society for Blood and Marrow Transplantation (EBMT) roadmap and perspectives to improve nutritional care in patients undergoing hematopoietic stem cell transplantation on behalf of the Cellular Therapy and Immunobiology Working Party (CTI
    Bone Marrow Transplant. 2023 Jul 5. doi: 10.1038/s41409-023-02018.
    PubMed     Abstract available


  95. PEREIRA EY, Cannell PK, Cooney J, Wright M, et al
    Bariatric surgery and allogeneic hematopoietic stem cell transplantation: a case series.
    Bone Marrow Transplant. 2023 Jul 1. doi: 10.1038/s41409-023-02026.
    PubMed    


    June 2023
  96. KORTLEVE JP, Kisch AM, Piepenbroek B, Mooyaart JE, et al
    Variation in hydration use after reinfusion of autologous stem cells in dimethyl sulfoxide (DMSO): a survey of EBMTcenters on behalf of the EBMT Nurses Group.
    Bone Marrow Transplant. 2023 Jun 30. doi: 10.1038/s41409-023-02008.
    PubMed    


  97. CASSANELLO G, Serpenti F, Bagnoli F, Saporiti G, et al
    Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
    Bone Marrow Transplant. 2023 Jun 24. doi: 10.1038/s41409-023-02023.
    PubMed    


  98. MOOKERJEE A, Gupta R, Kumar R, Sharma A, et al
    Dual assessment with multiparameter flow cytometry and (18)F-FDG PET/CT scan provides enhanced prediction of measurable residual disease after autologous haemopoietic stem cell transplant in myeloma-a prospective study.
    Bone Marrow Transplant. 2023 Jun 16. doi: 10.1038/s41409-023-02017.
    PubMed    


  99. VON ASMUTH EGJ, Putter H, Mohseny AB, Schilham MW, et al
    Automating outcome analysis after stem cell transplantation: The YORT tool.
    Bone Marrow Transplant. 2023 Jun 6. doi: 10.1038/s41409-023-02009.
    PubMed     Abstract available


  100. MARRA JD, Galli E, Giammarco S, Chiusolo P, et al
    Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis.
    Bone Marrow Transplant. 2023 Jun 6. doi: 10.1038/s41409-023-02010.
    PubMed    


    May 2023
  101. NAGLER A, Labopin M, Swoboda R, Kulagin A, et al
    Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and
    Bone Marrow Transplant. 2023 May 30. doi: 10.1038/s41409-023-02012.
    PubMed     Abstract available


  102. ZHOU F, Pan T, Li X, Du F, et al
    Exploration of efficacy and safety of combined therapy of basiliximab with ruxolitinib for grade 3-4 steroid-refractory acute graft-versus-host disease: a registered clinical trial (NCT05021276).
    Bone Marrow Transplant. 2023 May 30. doi: 10.1038/s41409-023-02005.
    PubMed    


  103. DAENEN LGM, van der Bruggen JT, Leguit RJ, van der Wagen LE, et al
    Disseminated nontuberculous mycobacterial infections after allogeneic hematopoietic stem cell transplantation: a risk-based strategy for early diagnosis.
    Bone Marrow Transplant. 2023 May 20. doi: 10.1038/s41409-023-02011.
    PubMed    


  104. PALANIYANDI S, Strattan E, Kumari R, Mysinger M, et al
    Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.
    Bone Marrow Transplant. 2023 May 9. doi: 10.1038/s41409-023-02001.
    PubMed     Abstract available


  105. FILIPPINI VELAZQUEZ G, Labopin M, Tischer J, Raiola AM, et al
    Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Bone Marrow Transplant. 2023 May 9. doi: 10.1038/s41409-023-01985.
    PubMed     Abstract available


  106. WRIGHT C, Reid G, Lendrem BC, Hurst E, et al
    Host versus graft HLA-DP1 mismatching promotes graft versus host disease.
    Bone Marrow Transplant. 2023 May 6. doi: 10.1038/s41409-023-02003.
    PubMed    


  107. HIRSCHBUHL K, Labopin M, Polge E, Blaise D, et al
    Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2023 May 5. doi: 10.1038/s41409-023-01966.
    PubMed     Abstract available


  108. HUBBEN A, Dima D, Atieh T, Chaulagain C, et al
    On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone.
    Bone Marrow Transplant. 2023;58:610-612.
    PubMed    


    April 2023
  109. GAO Y, Wu H, Shi Z, Gao F, et al
    Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Apr 29. doi: 10.1038/s41409-023-01989.
    PubMed     Abstract available


  110. YUAN XL, Lai XY, Wu YB, Yang LX, et al
    A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation.
    Bone Marrow Transplant. 2023 Apr 18. doi: 10.1038/s41409-023-01979.
    PubMed     Abstract available


  111. MAHMOUDJAFARI Z, Alencar MC, Alexander MD, Johnson DJ, et al
    Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists.
    Bone Marrow Transplant. 2023 Apr 14. doi: 10.1038/s41409-023-01951.
    PubMed     Abstract available


  112. GOMEZ-ARTEAGA A, Orfali N, Pasciolla M, Baptiste A, et al
    Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD).
    Bone Marrow Transplant. 2023 Apr 12. doi: 10.1038/s41409-023-01981.
    PubMed    


  113. KONG J, Zheng FM, Wang ZD, Zhang YY, et al
    Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Apr 6. doi: 10.1038/s41409-023-01973.
    PubMed     Abstract available


    March 2023
  114. LUTHER M, Henes FO, Zabelina T, Massoud R, et al
    Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis.
    Bone Marrow Transplant. 2023 Mar 31. doi: 10.1038/s41409-023-01968.
    PubMed     Abstract available


  115. CHENG X, Huang R, Fan W, Huang S, et al
    The tear cytokine panel is a useful biomarker for early diagnosis and severity-evaluating of ocular chronic graft-versus-host disease.
    Bone Marrow Transplant. 2023 Mar 28. doi: 10.1038/s41409-023-01952.
    PubMed    


  116. ALTAREB M, Al-Awwami M, Alfraih F, Alhayli S, et al
    "Incidence and significance of donor-specific antibodies in haploidentical stem cell transplantation".
    Bone Marrow Transplant. 2023 Mar 23. doi: 10.1038/s41409-023-01950.
    PubMed     Abstract available


  117. CHOOLJIAN DM, Jacobs JW, Adkins BD, Savani BN, et al
    Trading tissues for freedom: incentivizing stem cell and solid organ donation in the incarcerated population.
    Bone Marrow Transplant. 2023 Mar 15. doi: 10.1038/s41409-023-01954.
    PubMed    


  118. EL CHEIKH J, Bidaoui G, Atoui A, Terro K, et al
    Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study.
    Bone Marrow Transplant. 2023 Mar 13. doi: 10.1038/s41409-023-01947.
    PubMed     Abstract available


  119. SACCARDI R, Putter H, Eikema DJ, Busto MP, et al
    Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE
    Bone Marrow Transplant. 2023 Mar 9. doi: 10.1038/s41409-023-01924.
    PubMed     Abstract available


  120. EBERHARDT KA, Jung V, Knops E, Heger E, et al
    CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality.
    Bone Marrow Transplant. 2023 Mar 3. doi: 10.1038/s41409-023-01944.
    PubMed     Abstract available


  121. WARTHMANN A, Holbro A, Buser A, Schefer S, et al
    BleedHD-a new electronic assessment tool for grading chronic graft-versus-host disease validated in a multicenter and multiprofessional setting.
    Bone Marrow Transplant. 2023 Mar 1. doi: 10.1038/s41409-023-01945.
    PubMed    


    February 2023
  122. PINANA JL, Martino R, Vazquez L, Lopez-Corral L, et al
    SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
    Bone Marrow Transplant. 2023 Feb 28:1-14. doi: 10.1038/s41409-023-01946.
    PubMed     Abstract available


  123. AGHEL N, Lui M, Wang V, Khalaf D, et al
    Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis.
    Bone Marrow Transplant. 2023 Feb 27. doi: 10.1038/s41409-023-01928.
    PubMed     Abstract available


  124. AVERBUCH D, de la Camara R, Tridello G, Knelange NS, et al
    Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and
    Bone Marrow Transplant. 2023 Feb 27:1-9. doi: 10.1038/s41409-023-01941.
    PubMed     Abstract available


  125. VINCI L, Flotho C, Noellke P, Lebrecht D, et al
    Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft.
    Bone Marrow Transplant. 2023 Feb 23. doi: 10.1038/s41409-023-01942.
    PubMed    


  126. NAGLER A, Labopin M, Swoboda R, Kulagin A, et al
    Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Par
    Bone Marrow Transplant. 2023 Feb 23. doi: 10.1038/s41409-023-01940.
    PubMed     Abstract available


  127. KAWAGUCHI K, Umeda K, Miyamoto S, Yoshida N, et al
    Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders.
    Bone Marrow Transplant. 2023 Feb 16. doi: 10.1038/s41409-023-01937.
    PubMed    


  128. CAPOFERRI G, Walti CS, Urwyler P, Ragozzino S, et al
    Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Feb 16. doi: 10.1038/s41409-023-01936.
    PubMed    


  129. HUANG Y, Luo C, Wu G, Huang X, et al
    Effects of donor-specific antibodies on engraftment and long-term survival after allogeneic hematopoietic stem cell transplantation-A systematic review and meta-analysis.
    Bone Marrow Transplant. 2023 Feb 13. doi: 10.1038/s41409-023-01932.
    PubMed     Abstract available


  130. MASSEI MS, Capolsini I, Mastrodicasa E, Perruccio K, et al
    HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia.
    Bone Marrow Transplant. 2023 Feb 11:1-8. doi: 10.1038/s41409-023-01911.
    PubMed     Abstract available


  131. MICHEL C, Robin M, Morisset S, Blaise D, et al
    Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS.
    Bone Marrow Transplant. 2023 Feb 11. doi: 10.1038/s41409-023-01931.
    PubMed     Abstract available


  132. MICHONNEAU D, Quignot N, Jiang H, Reichenbach D, et al
    Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France.
    Bone Marrow Transplant. 2023 Feb 10. doi: 10.1038/s41409-023-01930.
    PubMed     Abstract available


    January 2023
  133. HERGEL LLF, Kielsen K, Weischendorff S, Ifversen M, et al
    The macrophage activation marker sCD163 in acute and chronic graft-versus-host disease after pediatric hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Jan 31. doi: 10.1038/s41409-023-01927.
    PubMed    


  134. SUN YQ, Zhang XH, Jiang Q, Jiang H, et al
    Comparison of haploidentical hematopoietic stem cell transplantation with chemotherapy in older adults with acute myeloid leukemia.
    Bone Marrow Transplant. 2023 Jan 25. doi: 10.1038/s41409-023-01925.
    PubMed     Abstract available


  135. WASZCZUK-GAJDA A, Gras L, de Wreede LC, Sirait T, et al
    Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT.
    Bone Marrow Transplant. 2023 Jan 21. doi: 10.1038/s41409-023-01915.
    PubMed     Abstract available


  136. KATSUYA H, Yamaguchi K, Dung TC, Sano H, et al
    Late graft failure with donor-derived GPI-deficient cells in a mixed chimera following allogeneic bone marrow transplantation for severe aplastic anemia.
    Bone Marrow Transplant. 2023 Jan 21. doi: 10.1038/s41409-023-01923.
    PubMed    


  137. SROUR M, Alsuliman T, Labreuche J, Bulabois CE, et al
    Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of
    Bone Marrow Transplant. 2023 Jan 9. doi: 10.1038/s41409-022-01898.
    PubMed     Abstract available


    December 2022
  138. KIMURA SI, Shimizu H, Miyazaki T, Sakurai M, et al
    Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2022 Dec 26. doi: 10.1038/s41409-022-01901.
    PubMed    


  139. YANG F, Shi H, Xu T, Liu R, et al
    Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma.
    Bone Marrow Transplant. 2022 Dec 22. doi: 10.1038/s41409-022-01903.
    PubMed    


  140. CODA J, Raser K, Anand SM, Ghosh M, et al
    Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2022 Dec 22. doi: 10.1038/s41409-022-01906.
    PubMed    


  141. LIU W, Ji J, Zou D, Cao Y, et al
    Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China.
    Bone Marrow Transplant. 2022 Dec 17. doi: 10.1038/s41409-022-01899.
    PubMed    


  142. SANTORO N, Mooyaart JE, Devillier R, Koc Y, et al
    Correction: Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.
    Bone Marrow Transplant. 2022 Dec 14. doi: 10.1038/s41409-022-01855.
    PubMed    


  143. JAMY O, Dasher J, Chen A, Salzman D, et al
    Impact of pre-transplant individual comorbidities on risk of ICU admission and survival outcomes following allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Dec 12. doi: 10.1038/s41409-022-01897.
    PubMed     Abstract available


  144. LUECK C, Tzalavras A, Wohlfarth P, Meedt E, et al
    Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients.
    Bone Marrow Transplant. 2022 Dec 10. doi: 10.1038/s41409-022-01875.
    PubMed     Abstract available


  145. GARDIN A, Castelle M, Pichard S, Cano A, et al
    Long term follow-up after haematopoietic stem cell transplantation for mucopolysaccharidosis type I-H: a retrospective study of 51 patients.
    Bone Marrow Transplant. 2022 Dec 9. doi: 10.1038/s41409-022-01886.
    PubMed     Abstract available


  146. HARA J, Matsumoto K, Maeda N, Takahara-Matsubara M, et al
    Correction: High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors.
    Bone Marrow Transplant. 2022 Dec 8. doi: 10.1038/s41409-022-01890.
    PubMed    


  147. GOEL M, Eugster A, Schetelig J, Bonifacio E, et al
    Potential of TCR sequencing in graft-versus-host disease.
    Bone Marrow Transplant. 2022 Dec 7. doi: 10.1038/s41409-022-01885.
    PubMed     Abstract available


  148. SUN X, Fu H, Wang C, Zhang Y, et al
    Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection.
    Bone Marrow Transplant. 2022 Dec 1. doi: 10.1038/s41409-022-01880.
    PubMed     Abstract available


  149. LABERKO A, Sultanova E, Idarmacheva A, Skvortsova Y, et al
    Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity.
    Bone Marrow Transplant. 2022 Dec 1. doi: 10.1038/s41409-022-01883.
    PubMed     Abstract available


    November 2022
  150. MOISEEV I, Barabanshikova M, Dotsenko A, Smirnova A, et al
    First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens.
    Bone Marrow Transplant. 2022 Nov 30. doi: 10.1038/s41409-022-01879.
    PubMed     Abstract available


  151. ZHOU S, Ma X, Ma C, Zhu Q, et al
    Splenic irradiation combined with plasmapheresis and rituximab: a new option reducing donor-specific antibody in haploidentical hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Nov 19. doi: 10.1038/s41409-022-01868.
    PubMed    


  152. SHIMOMURA Y, Komukai S, Kitamura T, Sobue T, et al
    Identifying the optimal conditioning intensity for stem cell transplantation in patients with myelodysplastic syndrome: a machine learning analysis.
    Bone Marrow Transplant. 2022 Nov 14. pii: 10.1038/s41409-022-01871.
    PubMed     Abstract available


  153. LUO C, Wu G, Huang X, Ding Y, et al
    Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis.
    Bone Marrow Transplant. 2022 Nov 10. pii: 10.1038/s41409-022-01865.
    PubMed     Abstract available


  154. SOLH MM, Farnham C, Solomon SR, Bashey A, et al
    Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD).
    Bone Marrow Transplant. 2022 Nov 9. pii: 10.1038/s41409-022-01860.
    PubMed     Abstract available


  155. CHU M, Hu S, Shen Y, Shen D, et al
    Comparison of clinical outcomes between peripheral blood stem cells and peripheral blood stem cells plus bone marrow in myelodysplastic syndrome patients with haploidentical transplantation.
    Bone Marrow Transplant. 2022 Nov 5. pii: 10.1038/s41409-022-01862.
    PubMed     Abstract available


  156. XHAARD A, Villate A, Hamane S, Michonneau D, et al
    A 10-year retrospective analysis of Toxoplasma gondii qPCR screening in allogeneic hematopoietic stem cell transplantation recipients.
    Bone Marrow Transplant. 2022 Nov 5. pii: 10.1038/s41409-022-01861.
    PubMed     Abstract available


  157. SVEC P, Elfeky R, Galimard JE, Higham CS, et al
    Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study.
    Bone Marrow Transplant. 2022 Nov 4. pii: 10.1038/s41409-022-01852.
    PubMed     Abstract available


  158. HARA J, Matsumoto K, Maeda N, Takahara-Matsubara M, et al
    High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors.
    Bone Marrow Transplant. 2022 Nov 3. pii: 10.1038/s41409-022-01820.
    PubMed     Abstract available


    October 2022
  159. GOKARN A, Shenoy R, Punatar S, Mirgh S, et al
    Efficacy of artesunate for treatment of cytomegalovirus reactivation post allogeneic haematopoietic stem cell transplants.
    Bone Marrow Transplant. 2022 Oct 30. pii: 10.1038/s41409-022-01850.
    PubMed    


  160. ARCHER G, Berger I, Bondeelle L, de Margerie-Mellon C, et al
    Interstitial lung diseases after hematopoietic stem cell transplantation: New pattern of lung chronic graft-versus-host disease?
    Bone Marrow Transplant. 2022 Oct 29. pii: 10.1038/s41409-022-01859.
    PubMed     Abstract available


  161. ELGOHARY G, Toor AA, Gergis U
    Engraftment syndrome after allogeneic stem cell transplantation: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2022 Oct 25. pii: 10.1038/s41409-022-01849.
    PubMed     Abstract available


  162. RANGARAJAN HG, Crowell SA, Towerman AS, Shenoy SS, et al
    Correction to: CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease.
    Bone Marrow Transplant. 2022 Oct 19. pii: 10.1038/s41409-022-01854.
    PubMed    


  163. MOUHIEDDINE TH, Moshier E, Thibaud S, Puliafito B, et al
    Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support.
    Bone Marrow Transplant. 2022 Oct 19. pii: 10.1038/s41409-022-01848.
    PubMed     Abstract available


  164. GABELLI M, Stepensky P, Ottaviano G, Mullanfiroze K, et al
    Incremental donor lymphocyte infusion to treat mixed chimerism after allogeneic stem cell transplantation in children with non-malignant diseases.
    Bone Marrow Transplant. 2022 Oct 19. pii: 10.1038/s41409-022-01844.
    PubMed    


  165. XU L, Lu Y, Chen J, Sun S, et al
    Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results
    Bone Marrow Transplant. 2022 Oct 18. pii: 10.1038/s41409-022-01838.
    PubMed    


  166. YAO Z, Gu B, Zhang Y, Qi J, et al
    CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2022 Oct 17. pii: 10.1038/s41409-022-01845.
    PubMed    


  167. YOSHIDA S, Ara T, Okada K, Mori Y, et al
    The preceding hyponatremia is a useful hallmark for the diagnosis of HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Oct 15. pii: 10.1038/s41409-022-01843.
    PubMed    


  168. BANET A, Bazarbachi A, Labopin M, Stocker N, et al
    Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2022 Oct 12. pii: 10.1038/s41409-022-01841.
    PubMed     Abstract available


  169. SANTORO N, Mooyaart JE, Devillier R, Koc Y, et al
    Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.
    Bone Marrow Transplant. 2022 Oct 10. pii: 10.1038/s41409-022-01839.
    PubMed     Abstract available


  170. ZAMA D, Masetti R, Baccelli F, Leardini D, et al
    Antibiotic prophylaxis and management of infections in pediatric hematopoietic stem cell transplantation: a survey from the Stem Cell Transplant and the Infectious Disease Working Groups of the AIEOP network.
    Bone Marrow Transplant. 2022 Oct 7. pii: 10.1038/s41409-022-01793.
    PubMed    


  171. BACKHAUS D, Brauer D, Pointner R, Bischof L, et al
    A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older.
    Bone Marrow Transplant. 2022 Oct 4. pii: 10.1038/s41409-022-01833.
    PubMed     Abstract available


  172. LAHTINEN AK, Koski J, Ritari J, Hyvarinen K, et al
    Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2022 Oct 4. pii: 10.1038/s41409-022-01828.
    PubMed     Abstract available


  173. FERNANDEZ-SOJO J, Horton R, Cid J, Azqueta C, et al
    Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry.
    Bone Marrow Transplant. 2022;57:1531-1538.
    PubMed     Abstract available


    September 2022
  174. QIAO X, Bilinski J, Wang L, Yang T, et al
    Safety and efficacy of fecal microbiota transplantation in the treatment of graft-versus-host disease.
    Bone Marrow Transplant. 2022 Sep 27. pii: 10.1038/s41409-022-01824.
    PubMed     Abstract available


  175. JUNG SH, Min CK, Lee JH, Mun YC, et al
    Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909).
    Bone Marrow Transplant. 2022 Sep 22. pii: 10.1038/s41409-022-01818.
    PubMed     Abstract available


  176. BARANWAL A, Mangaonkar A, Shah MV, Litzow MR, et al
    High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant.
    Bone Marrow Transplant. 2022 Sep 21. pii: 10.1038/s41409-022-01829.
    PubMed    


  177. MULAS O, Caocci G, Efficace F, Piras E, et al
    Long-term health-related quality of life in patients with beta-thalassemia after unrelated hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Sep 16. pii: 10.1038/s41409-022-01823.
    PubMed    


  178. PIZZOLA CJ, Cioccio J, Rakszawski KL, Nickolich M, et al
    Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities.
    Bone Marrow Transplant. 2022 Sep 12. pii: 10.1038/s41409-022-01821.
    PubMed    


  179. ATSUTA Y, Sugita J, Nakamae H, Maruyama Y, et al
    Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation.
    Bone Marrow Transplant. 2022 Sep 12. pii: 10.1038/s41409-022-01822.
    PubMed     Abstract available


  180. KUANG P, Lin T, Chen X, Yang Y, et al
    Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells.
    Bone Marrow Transplant. 2022 Sep 8. pii: 10.1038/s41409-022-01789.
    PubMed    


  181. SPYRIDONIDIS A, Labopin M, Brissot E, Moiseev I, et al
    Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2022 Sep 7. pii: 10.1038/s41409-022-01816.
    PubMed     Abstract available


  182. TANG B, Cai Z, Wang Z, Lin D, et al
    Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2022 Sep 2. pii: 10.1038/s41409-022-01797.
    PubMed     Abstract available


  183. PECI F, Dekker L, Pagliaro A, van Boxtel R, et al
    The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2022;57:1357-1364.
    PubMed     Abstract available


    August 2022
  184. QI HZ, Xu J, Yang QQ, Lin R, et al
    Effect of pediatric- versus adult-type chemotherapy regimens on outcomes of allogeneic hematopoietic stem cell transplants for adult T-cell acute lymphoblastic leukemia in first complete remission.
    Bone Marrow Transplant. 2022 Aug 30. pii: 10.1038/s41409-022-01796.
    PubMed     Abstract available


  185. FILE B, Gergis M, Gergis U
    The effect of hematopoietic stem cell transplantation on fertility and strategies for improvement.
    Bone Marrow Transplant. 2022 Aug 29. pii: 10.1038/s41409-022-01792.
    PubMed     Abstract available


  186. ELLIOTT J, Ahlawat S, Prince HM, Kennedy G, et al
    Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides.
    Bone Marrow Transplant. 2022 Aug 26. pii: 10.1038/s41409-022-01787.
    PubMed    


  187. SILBERT S, Cole K, Bedoya SZ, Freeman AF, et al
    Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency.
    Bone Marrow Transplant. 2022 Aug 23. pii: 10.1038/s41409-022-01778.
    PubMed    


  188. JACOBSEN ED, Kim HT, Jeter E, Jacobson C, et al
    Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2022 Aug 22. pii: 10.1038/s41409-022-01784.
    PubMed    


  189. NAGLER A, Tsirigotis P
    Donor lymphocyte infusion (DLI) post haploidentical stem cell transplantation (Haplo) with post-transplant cyclophosphamide (PTCy): crossing the human leukocyte antigen (HLA) barrier.
    Bone Marrow Transplant. 2022 Aug 22. pii: 10.1038/s41409-022-01785.
    PubMed    


  190. SUGITA J, Atsuta Y, Nakamae H, Maruyama Y, et al
    Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation.
    Bone Marrow Transplant. 2022 Aug 20. pii: 10.1038/s41409-022-01770.
    PubMed     Abstract available


  191. BI X, Gergis U, Wagner JL, Carabasi M, et al
    Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies.
    Bone Marrow Transplant. 2022 Aug 19. pii: 10.1038/s41409-022-01780.
    PubMed     Abstract available


  192. YUAN Y, Wong P, Butler JP, Henden A, et al
    High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantation.
    Bone Marrow Transplant. 2022 Aug 15. pii: 10.1038/s41409-022-01773.
    PubMed    


  193. BARANWAL A, Byun J, Ritz E, Kadanagowd A, et al
    Myeloablative TBI is associated with increased risk of pulmonary GVHD in patients undergoing allogeneic hematopoietic stem cell transplant.
    Bone Marrow Transplant. 2022 Aug 15. pii: 10.1038/s41409-022-01779.
    PubMed    


  194. HANNA P, Strohbehn I, Moreno D, Harden D, et al
    Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma.
    Bone Marrow Transplant. 2022 Aug 3. pii: 10.1038/s41409-022-01767.
    PubMed    


  195. KANG KR, Kim YJ, Ahn MB, Kang HM, et al
    Shorter duration of protection and lower geometric mean titers against A/H3N2 antigen of the quadrivalent influenza vaccine in children post-allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Aug 1. pii: 10.1038/s41409-022-01768.
    PubMed    


    July 2022
  196. MA J, Sun S, Hu Y, Wu M, et al
    Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL.
    Bone Marrow Transplant. 2022 Jul 25. pii: 10.1038/s41409-022-01766.
    PubMed    


  197. PRABAHRAN A, Koldej R, Chee L, Szer J, et al
    Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review.
    Bone Marrow Transplant. 2022 Jul 23. pii: 10.1038/s41409-022-01761.
    PubMed     Abstract available


  198. BUSCA A, Gabrielli G, Sidoti F, Costa C, et al
    SARS-CoV-2 infection in a stem cell transplant recipient grafted from a SARS-CoV-2-positive donor.
    Bone Marrow Transplant. 2022 Jul 16. pii: 10.1038/s41409-022-01763.
    PubMed    


  199. ZU Y, Li Z, Gui R, Liu Y, et al
    Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre,
    Bone Marrow Transplant. 2022 Jul 15. pii: 10.1038/s41409-022-01754.
    PubMed     Abstract available


  200. DE KLOET LC, Bense JE, van der Stoep MYEC, Louwerens M, et al
    Late endocrine effects after hematopoietic stem cell transplantation in children with nonmalignant diseases.
    Bone Marrow Transplant. 2022 Jul 15. pii: 10.1038/s41409-022-01755.
    PubMed     Abstract available


  201. MERLI P, Massa M, Russo A, Rea F, et al
    Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient.
    Bone Marrow Transplant. 2022 Jul 14. pii: 10.1038/s41409-022-01752.
    PubMed    


  202. MASSOUD R, Klyuchnikov E, Gagelmann N, Zabelina T, et al
    Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation.
    Bone Marrow Transplant. 2022 Jul 13. pii: 10.1038/s41409-022-01666.
    PubMed     Abstract available


  203. JAMY O, Arora S, Meredith R, Salzman D, et al
    Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy.
    Bone Marrow Transplant. 2022 Jul 9. pii: 10.1038/s41409-022-01757.
    PubMed    


  204. TSAMADOU C, Gowdavally S, Platzbecker U, Sala E, et al
    Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Jul 8. pii: 10.1038/s41409-022-01751.
    PubMed     Abstract available


  205. JACOBS JW, Adkins BD, Wheeler AP, Booth GS, et al
    Diversity, equity, and inclusion in transfusion medicine, blood donation, and blood and bone marrow transplantation: language matters.
    Bone Marrow Transplant. 2022 Jul 8. pii: 10.1038/s41409-022-01758.
    PubMed    


  206. HASHMI S, Ram R
    The great Lazar-a Graft-versus-host-disease patient!
    Bone Marrow Transplant. 2022 Jul 8. pii: 10.1038/s41409-022-01707.
    PubMed    


  207. RANGARAJAN HG, Crowell SA, Towerman AS, Shenoy SS, et al
    CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease.
    Bone Marrow Transplant. 2022 Jul 7. pii: 10.1038/s41409-022-01749.
    PubMed    


  208. MARCAIS A, Mahlaoui N, Neven B, Lanternier F, et al
    Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiency.
    Bone Marrow Transplant. 2022 Jul 6. pii: 10.1038/s41409-022-01739.
    PubMed     Abstract available


  209. YINGLING SK, Gonzalez RM, Dillaman M, Seago K, et al
    Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization.
    Bone Marrow Transplant. 2022;57:1194-1197.
    PubMed    


  210. DING L, Han DM, Yan HM, Zhou JX, et al
    Infusion of haploidentical HSCs combined with allogenic MSCs for the treatment of ALL patients.
    Bone Marrow Transplant. 2022;57:1086-1094.
    PubMed     Abstract available


    June 2022
  211. NAGLER A, Labopin M, Cornelissen JJ, Forcade E, et al
    Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Socie
    Bone Marrow Transplant. 2022 Jun 30. pii: 10.1038/s41409-022-01742.
    PubMed     Abstract available


  212. LE BRIS Y, Costes D, Bourgade R, Guillaume T, et al
    Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies.
    Bone Marrow Transplant. 2022 Jun 28. pii: 10.1038/s41409-022-01747.
    PubMed     Abstract available


  213. SELVARAJAN S, Tammiraju S, Lionel S, Kulkarni U, et al
    Cyclophosphamide induced haemorrhagic myocarditis-pericarditis: a rare but lethal complication in the setting of allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2022 Jun 27. pii: 10.1038/s41409-022-01745.
    PubMed    


  214. LEMAIRE B, Combescure C, Chalandon Y, Vuilleumier N, et al
    Kinetics of disappearance and appearance of isoagglutinins A and B after ABO-incompatible hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Jun 25. pii: 10.1038/s41409-022-01737.
    PubMed     Abstract available


  215. HOLTAN SG, Yu J, Paranagama D, Tang J, et al
    Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study.
    Bone Marrow Transplant. 2022 Jun 23. pii: 10.1038/s41409-022-01736.
    PubMed     Abstract available


  216. TANG L, Wu Y, Lei R, Liu J, et al
    Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes.
    Bone Marrow Transplant. 2022 Jun 22. pii: 10.1038/s41409-022-01729.
    PubMed    


  217. PEROVIC V, Sabol I, Grce M, Inngjerdingen M, et al
    Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network.
    Bone Marrow Transplant. 2022 Jun 11. pii: 10.1038/s41409-022-01733.
    PubMed    


  218. LAZZARI L, Balaguer-Rosello A, Montoro J, Greco R, et al
    Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
    Bone Marrow Transplant. 2022 Jun 9. pii: 10.1038/s41409-022-01725.
    PubMed     Abstract available


  219. SONG Y, Chen S, Roseman J, Scigliano E, et al
    Patient-generated strategies for strengthening adherence to multiple medication regimens after allogeneic stem cell transplantation: a qualitative study.
    Bone Marrow Transplant. 2022 Jun 9. pii: 10.1038/s41409-022-01727.
    PubMed    


  220. LIU Y, Duan Z, Li F, Zhang X, et al
    Acute kidney injury in peripheral blood haploidentical hematopoietic stem cell transplantation: should attract enough attention.
    Bone Marrow Transplant. 2022 Jun 7. pii: 10.1038/s41409-022-01731.
    PubMed    


  221. ELHADAD S, Chadburn A, Magro C, Van Besien K, et al
    C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy.
    Bone Marrow Transplant. 2022 Jun 4. pii: 10.1038/s41409-022-01723.
    PubMed    


  222. TAMAKI M, Matsumi S, Nakasone H, Nakamura Y, et al
    Interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibody after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Jun 4. pii: 10.1038/s41409-022-01730.
    PubMed     Abstract available


  223. HANNA P, Strohbehn I, Wang Q, Frigault M, et al
    Acute kidney injury caused by haplostorm after allogenic hematopoietic stem cell transplant.
    Bone Marrow Transplant. 2022 Jun 4. pii: 10.1038/s41409-022-01720.
    PubMed    


  224. RUESCH M, Amar El Dusouqui S, Buhrfeind E, Buser A, et al
    Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors - first 10 years of prospective donor follow-up of Swiss donors.
    Bone Marrow Transplant. 2022;57:918-924.
    PubMed     Abstract available


    May 2022
  225. PESSOA JM, da Rosa EL, Americo AD, Motta CL, et al
    Cryopreserved versus non-cryopreserved stem cell autografts in multiple myeloma a restrospective cohort study.
    Bone Marrow Transplant. 2022 May 30. pii: 10.1038/s41409-022-01718.
    PubMed     Abstract available


  226. WELLS JR, Kang G, Suliman AY, Li Y, et al
    Delayed platelet recovery and mortality after allogeneic stem cell transplantation in children.
    Bone Marrow Transplant. 2022 May 28. pii: 10.1038/s41409-022-01726.
    PubMed    


  227. NISHIDA M, Sugita J, Iwai T, Sato M, et al
    Ultrasonographic scoring system of late-onset sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 May 25. pii: 10.1038/s41409-022-01717.
    PubMed    


  228. FERNANDEZ-SOJO J, Cid J, Azqueta C, Valdivia E, et al
    Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation.
    Bone Marrow Transplant. 2022 May 25. pii: 10.1038/s41409-022-01722.
    PubMed    


  229. ANDERSSON BS, Thall PF, Ma J, Valdez BC, et al
    A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan +/- clofarabine in allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2022 May 24. pii: 10.1038/s41409-022-01705.
    PubMed     Abstract available


  230. LINGBLOM C, Andersson K, Johansson JE, Wenneras C, et al
    Multivariate modeling of eosinophil markers and other cellular immune parameters associated with the development of chronic graft-versus-host disease.
    Bone Marrow Transplant. 2022 May 23. pii: 10.1038/s41409-022-01708.
    PubMed    


  231. ANGELOV D, Dillon J, Mellerick L, Pender E, et al
    Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease.
    Bone Marrow Transplant. 2022 May 20. pii: 10.1038/s41409-022-01713.
    PubMed    


  232. AMONOO HL, Harnedy LE, Deary EC, Traeger L, et al
    Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study.
    Bone Marrow Transplant. 2022 May 19. pii: 10.1038/s41409-022-01711.
    PubMed     Abstract available


  233. ALEXANDER T, Greco R
    Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Bone Marrow Transplant. 2022 May 16. pii: 10.1038/s41409-022-01702.
    PubMed     Abstract available


  234. KUSKONMAZ B, Ayvaz D, Okur FV, Aydin B, et al
    First allogeneic hematopoietic stem cell transplantation in RASGRP1 deficiency: long-term follow-up.
    Bone Marrow Transplant. 2022 May 14. pii: 10.1038/s41409-022-01704.
    PubMed    


  235. DANYLESKO I, Peczynski C, Labopin M, Polge E, et al
    Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT.
    Bone Marrow Transplant. 2022 May 13. pii: 10.1038/s41409-022-01695.
    PubMed     Abstract available


  236. FRIETSCH JJ, Miethke J, Linke P, Crodel CC, et al
    Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2022 May 10. pii: 10.1038/s41409-022-01701.
    PubMed     Abstract available


  237. PENGLASE R, Englert H, Tymms K, Carr A, et al
    Successful lymphoablative autologous haematopoietic stem cell transplantation in three cases of severe autoimmune disease despite reduced dose cyclophosphamide conditioning-do we need 200 mg/kg cyclophosphamide?
    Bone Marrow Transplant. 2022 May 6. pii: 10.1038/s41409-022-01696.
    PubMed    


  238. WIECZOREK M, Mariotto S, Ferrari S, Mosna F, et al
    Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series.
    Bone Marrow Transplant. 2022 May 5. pii: 10.1038/s41409-022-01690.
    PubMed     Abstract available


  239. OHASHI T, Aoki J, Ando T, Ishiyama Y, et al
    Clinical impact of cigarette smoking on the outcomes of allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Bone Marrow Transplant. 2022 May 3. pii: 10.1038/s41409-022-01678.
    PubMed     Abstract available


  240. WADA F, Kondo T, Yamamoto R, Yamagiwa T, et al
    Addition and drug monitoring of mycophenolate mofetil for GVHD prophylaxis in unrelated bone marrow transplantation.
    Bone Marrow Transplant. 2022 May 2. pii: 10.1038/s41409-022-01692.
    PubMed    


    April 2022
  241. AL SALEH AS, Alghamdi AI, Alzahrani M, Alahmari B, et al
    Rates and predictors of infusion-related reactions in patients receiving standard versus prolonged infusion of rabbit anti-thymocyte globulin for hematopoietic stem cell transplantation, a retrospective analysis.
    Bone Marrow Transplant. 2022 Apr 30. pii: 10.1038/s41409-022-01694.
    PubMed    


  242. LIANG H, Pan L, Xie Y, Fan J, et al
    Health-related quality of life in pediatric patients with beta-thalassemia major after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Apr 29. pii: 10.1038/s41409-022-01663.
    PubMed     Abstract available


  243. NAWAS MT, Lee JO, Flynn J, Maloy M, et al
    CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis.
    Bone Marrow Transplant. 2022 Apr 28. pii: 10.1038/s41409-022-01684.
    PubMed     Abstract available


  244. SOLA M, Bhatt V, Palazzo M, Cavalier KE, et al
    Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant.
    Bone Marrow Transplant. 2022 Apr 27. pii: 10.1038/s41409-022-01689.
    PubMed     Abstract available


  245. ZHANG R, Lu X, Tang LV, Wang HF, et al
    Comparative analysis of Decitabine intensified BUCY2 and BUCY2 conditioning regimen for high-risk MDS patients undergoing allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Apr 22. pii: 10.1038/s41409-022-01645.
    PubMed     Abstract available


  246. NIEDERWIESER C, Weber B, Reichard M, Gagelmann N, et al
    Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19.
    Bone Marrow Transplant. 2022 Apr 20. pii: 10.1038/s41409-022-01660.
    PubMed    


  247. DELIA M, Carluccio P, Gagliardi VP, Mestice A, et al
    Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation.
    Bone Marrow Transplant. 2022 Apr 19. pii: 10.1038/s41409-022-01676.
    PubMed    


  248. SALHOTRA A, Talley M, Wu X, Tsai W, et al
    Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease.
    Bone Marrow Transplant. 2022 Apr 19. pii: 10.1038/s41409-022-01671.
    PubMed    


  249. SCHROEDER MA, Hari PN, Blithe A, Paranagama D, et al
    Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.
    Bone Marrow Transplant. 2022 Apr 18. pii: 10.1038/s41409-022-01673.
    PubMed     Abstract available


  250. SCHENONE L, Houillier C, Tanguy ML, Choquet S, et al
    Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
    Bone Marrow Transplant. 2022 Apr 14. pii: 10.1038/s41409-022-01648.
    PubMed     Abstract available


  251. LAZANA I, Floro L, Christmas T, Shah S, et al
    Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option.
    Bone Marrow Transplant. 2022 Apr 12. pii: 10.1038/s41409-022-01657.
    PubMed     Abstract available


  252. MASOOD A, Wahab A, Iqbal Q, Davis J, et al
    Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature.
    Bone Marrow Transplant. 2022 Apr 11. pii: 10.1038/s41409-022-01668.
    PubMed     Abstract available


  253. SHIPTON MJ, Kinsella PM, Davis T, Azzato F, et al
    Infective hyperammonaemic encephalopathy after allogeneic stem cell transplant.
    Bone Marrow Transplant. 2022 Apr 11. pii: 10.1038/s41409-022-01669.
    PubMed    


  254. JORIS MM, Schmidt AH, Bernas SN, Feinberg J, et al
    Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor Association.
    Bone Marrow Transplant. 2022 Apr 9. pii: 10.1038/s41409-022-01667.
    PubMed    


  255. PIEVANI A, Granata V, Desantis G, Antolini L, et al
    CD14 positive cells accelerate hematopoietic stem cell engraftment.
    Bone Marrow Transplant. 2022 Apr 8. pii: 10.1038/s41409-022-01662.
    PubMed     Abstract available


  256. LIU H, Liu W, Li R, Jiao Y, et al
    A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.
    Bone Marrow Transplant. 2022 Apr 7. pii: 10.1038/s41409-022-01655.
    PubMed    


  257. COOK J, Gonsalves WI, Gertz MA, Visram A, et al
    Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.
    Bone Marrow Transplant. 2022 Apr 2. pii: 10.1038/s41409-022-01659.
    PubMed    


  258. MCCANN SR
    Choices: peripheral blood or marrow: natural or cloned yeasts.
    Bone Marrow Transplant. 2022;57:524-525.
    PubMed    


    March 2022
  259. JANSSEN MJM, Bruns AHW, Verduyn Lunel FM, Raijmakers RAP, et al
    Correction to: Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2022 Mar 31. pii: 10.1038/s41409-022-01651.
    PubMed    


  260. SCHNEIDEWIND L, Neumann T, Peters N, Kranz J, et al
    Significance of men's health in long-term survivors of allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2022 Mar 25. pii: 10.1038/s41409-022-01638.
    PubMed    


  261. MACHOWICZ R, Suarez F, Wiktor-Jedrzejczak W, Eikema DJ, et al
    Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT.
    Bone Marrow Transplant. 2022 Mar 24. pii: 10.1038/s41409-022-01634.
    PubMed     Abstract available


  262. JIANG JL, Chen M, Wang LN, Wan M, et al
    Double alkylators based conditioning reduced the relapse rate after allogeneic peripheral blood stem cell transplantation in adult patients with myeloid malignancies: a single arm phase II study.
    Bone Marrow Transplant. 2022 Mar 24. pii: 10.1038/s41409-022-01643.
    PubMed    


  263. ANDRE I, Simons L, Ma K, Moirangthem RD, et al
    Correction to: Ex vivo generated human T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic stem cell transplantation or after gene therapy.
    Bone Marrow Transplant. 2022 Mar 16. pii: 10.1038/s41409-022-01629.
    PubMed    


  264. KARAM D, Gertz M, Lacy M, Dispenzieri A, et al
    Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant.
    Bone Marrow Transplant. 2022 Mar 16. pii: 10.1038/s41409-022-01631.
    PubMed     Abstract available


  265. UENO T, Ohta T, Sugio Y, Ohno Y, et al
    Severe acute interstitial lung disease after BNT162b2 mRNA COVID-19 vaccination in a patient post HLA-haploidentical hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Mar 10. pii: 10.1038/s41409-022-01633.
    PubMed    


  266. GALLI E, Sora F, Hohaus S, Bellesi S, et al
    Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma.
    Bone Marrow Transplant. 2022 Mar 8. pii: 10.1038/s41409-022-01632.
    PubMed    


  267. PAHNKE S, Nygell UA, Johansson JE, Kisch A, et al
    Cancer incidence in healthy Swedish peripheral blood stem cell donors.
    Bone Marrow Transplant. 2022 Mar 7. pii: 10.1038/s41409-022-01617.
    PubMed     Abstract available


  268. EL JURDI N, Okoev G, DeFor TE, Holtan SG, et al
    Predictors and outcomes of flares in chronic graft-versus-host disease.
    Bone Marrow Transplant. 2022 Mar 5. pii: 10.1038/s41409-022-01628.
    PubMed     Abstract available


    February 2022
  269. ZHANG Z, Hasegawa Y, Hashimoto D, Senjo H, et al
    Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Feb 28. pii: 10.1038/s41409-022-01619.
    PubMed     Abstract available


  270. FORCADE E, Chevret S, Finke J, Ehninger G, et al
    Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2022 Feb 26. pii: 10.1038/s41409-022-01620.
    PubMed     Abstract available


  271. YESILIPEK MA, Uygun V, Kupesiz A, Karasu G, et al
    Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience.
    Bone Marrow Transplant. 2022 Feb 24. pii: 10.1038/s41409-022-01613.
    PubMed     Abstract available


  272. LINDAHL H, Vonlanthen S, Valentini D, Bjorklund AT, et al
    Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Bone Marrow Transplant. 2022 Feb 24. pii: 10.1038/s41409-022-01615.
    PubMed     Abstract available


  273. ARSLAN S, Ali H, Mei M, Marcucci G, et al
    Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib.
    Bone Marrow Transplant. 2022 Feb 22. pii: 10.1038/s41409-022-01590.
    PubMed    


  274. HUTT D, Arjona ET, Mekelenkamp H, Galimard JE, et al
    Safe transfer of pediatric patients from hematopoietic stem cell transplant unit into the pediatric intensive care unit: views of nurses and physicians.
    Bone Marrow Transplant. 2022 Feb 21. pii: 10.1038/s41409-021-01559.
    PubMed     Abstract available


  275. MADANCHI R, Engel NW, Alsdorf W, Oing C, et al
    Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients.
    Bone Marrow Transplant. 2022 Feb 21. pii: 10.1038/s41409-022-01614.
    PubMed     Abstract available


  276. MORENO-CASTANO AB, Palomo M, Torramade-Moix S, Martinez-Sanchez J, et al
    An endothelial proinflammatory phenotype precedes the development of the engraftment syndrome after autologous Hct.
    Bone Marrow Transplant. 2022 Feb 18. pii: 10.1038/s41409-022-01610.
    PubMed     Abstract available


  277. LEIMI L, Jahnukainen K, Olkinuora H, Meri S, et al
    Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Feb 17. pii: 10.1038/s41409-022-01607.
    PubMed     Abstract available


  278. YOON SE, Jo H, Kang ES, Cho D, et al
    Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis.
    Bone Marrow Transplant. 2022 Feb 16. pii: 10.1038/s41409-022-01605.
    PubMed     Abstract available


  279. DROZDOV D, Petermann K, Dougoud S, Oberholzer S, et al
    Dynamics of recent thymic emigrants in pediatric recipients of allogeneic hematopoetic stem cell transplantation.
    Bone Marrow Transplant. 2022 Feb 9. pii: 10.1038/s41409-022-01594.
    PubMed     Abstract available


  280. SUH JK, Im HJ, Kang SH, Kim H, et al
    Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases.
    Bone Marrow Transplant. 2022 Feb 7. pii: 10.1038/s41409-021-01556.
    PubMed    


  281. PIEMONTESE S, Lazzari L, Ruggeri A, Marcatti M, et al
    Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience.
    Bone Marrow Transplant. 2022 Feb 5. pii: 10.1038/s41409-022-01600.
    PubMed    


  282. GEVORGIAN AG, Kozlov AV, Tolkunova PS, Kazantzev IV, et al
    Tandem autologous hematopoietic stem cell transplantation for embryonal brain tumors in infants and very young children.
    Bone Marrow Transplant. 2022 Feb 3. pii: 10.1038/s41409-022-01593.
    PubMed     Abstract available


  283. PARSONS SK, Rodday AM, Weidner RA, Morris E, et al
    Significant improvement of child physical and emotional functioning after familial haploidentical stem cell transplant.
    Bone Marrow Transplant. 2022 Feb 2. pii: 10.1038/s41409-022-01584.
    PubMed     Abstract available


  284. LINDHOLM C, Olofsson E, Creignou M, Nilsson L, et al
    Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study.
    Bone Marrow Transplant. 2022 Feb 2. pii: 10.1038/s41409-022-01582.
    PubMed     Abstract available


  285. FRIEND BD, Muhsen IN, Patel S, Hill LC, et al
    Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
    Bone Marrow Transplant. 2022 Feb 1. pii: 10.1038/s41409-022-01599.
    PubMed     Abstract available


  286. NAGLER A, Labopin M, Huang XJ, Blaise D, et al
    Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.
    Bone Marrow Transplant. 2022 Feb 1. pii: 10.1038/s41409-021-01537.
    PubMed     Abstract available


    January 2022
  287. FILE B, Huang Y, Peedin A, Gergis U, et al
    The impact of HLA donor-specific antibodies on engraftment and the evolving desensitization strategies.
    Bone Marrow Transplant. 2022 Jan 26. pii: 10.1038/s41409-022-01578.
    PubMed     Abstract available


  288. SKEENS M, Guttoo P, Stanek JR, Taylor K, et al
    An Exploration of COVID-19 Impact and Vaccine Hesitancy in Parents of Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients.
    Bone Marrow Transplant. 2022 Jan 24. pii: 10.1038/s41409-022-01587.
    PubMed     Abstract available


  289. NI F, Yin ETS, Zhou L, Zhao H, et al
    Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion.
    Bone Marrow Transplant. 2022 Jan 24. pii: 10.1038/s41409-021-01554.
    PubMed    


  290. UTSUNOMIYA A, Tokunaga M, Nakano N, Fujiwara H, et al
    Long-term follow-up of patients with ATL after autologous stem cell transplantation.
    Bone Marrow Transplant. 2022 Jan 23. pii: 10.1038/s41409-021-01412.
    PubMed    


  291. KAWAJIRI A, Kawase T, Tanaka H, Fukuda T, et al
    Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation.
    Bone Marrow Transplant. 2022 Jan 21. pii: 10.1038/s41409-021-01552.
    PubMed     Abstract available


  292. MANNINA D, Badbaran A, Wolschke C, Klyuchnikov E, et al
    Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis.
    Bone Marrow Transplant. 2022 Jan 19. pii: 10.1038/s41409-022-01566.
    PubMed    


  293. JEPPESEN H, Kielsen K, Siersma V, Lindegaard J, et al
    Ocular graft-versus-host disease and dry eye disease after paediatric haematopoietic stem cell transplantation - incidence and risk factors.
    Bone Marrow Transplant. 2022 Jan 18. pii: 10.1038/s41409-022-01564.
    PubMed     Abstract available


  294. HASHMI H, Shockley A, Davis JA
    'Save the day with a Stem Cell Rescue': Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy.
    Bone Marrow Transplant. 2022 Jan 17. pii: 10.1038/s41409-022-01570.
    PubMed    


  295. SHAO DF, Li JH, Hu T, Zhang ZX, et al
    Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring.
    Bone Marrow Transplant. 2022 Jan 17. pii: 10.1038/s41409-021-01545.
    PubMed     Abstract available


  296. SHIMONI A
    Relapse of acute leukemia after a second allogeneic stem- cell transplantation; Is there any hope for cure?
    Bone Marrow Transplant. 2022 Jan 14. pii: 10.1038/s41409-021-01508.
    PubMed    


  297. SOERENSEN JF, Aggerholm A, Rosenberg CA, Bill M, et al
    Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation.
    Bone Marrow Transplant. 2022 Jan 13. pii: 10.1038/s41409-022-01567.
    PubMed     Abstract available


  298. SHIMONI A, Labopin M, Angelucci E, Blaise D, et al
    The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML.
    Bone Marrow Transplant. 2022 Jan 13. pii: 10.1038/s41409-021-01493.
    PubMed     Abstract available


  299. TRUNK AD, Shewan SK, Lee CJ, Parker CJ, et al
    Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination.
    Bone Marrow Transplant. 2022 Jan 11. pii: 10.1038/s41409-021-01543.
    PubMed    


  300. VINCENT L, Gras L, Ceballos P, Finke J, et al
    Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.
    Bone Marrow Transplant. 2022 Jan 10. pii: 10.1038/s41409-021-01560.
    PubMed    


  301. LOSCHI M, Roux C, Sudaka I, Ferrero-Vacher C, et al
    Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.
    Bone Marrow Transplant. 2022 Jan 9. pii: 10.1038/s41409-021-01544.
    PubMed     Abstract available


  302. EL HUSSEIN S, DiNardo CD, Takahashi K, Khoury JD, et al
    Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.
    Bone Marrow Transplant. 2022 Jan 7. pii: 10.1038/s41409-021-01538.
    PubMed     Abstract available


  303. ANDOLINA JR, Wang YC, Ji L, Freyer DR, et al
    Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience.
    Bone Marrow Transplant. 2022 Jan 6. pii: 10.1038/s41409-021-01558.
    PubMed     Abstract available


  304. STUTZ L, Halter JP, Heim D, Passweg JR, et al
    Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin.
    Bone Marrow Transplant. 2022 Jan 4. pii: 10.1038/s41409-021-01546.
    PubMed     Abstract available


  305. VELIER M, Daumas A, Simoncini S, Arcani R, et al
    Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis.
    Bone Marrow Transplant. 2022;57:17-22.
    PubMed     Abstract available


    December 2021
  306. BETHGE WA, Eyrich M, Mielke S, Meisel R, et al
    Results of a multicenter phase I/II trial of TCRalphabeta and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients.
    Bone Marrow Transplant. 2021 Dec 24. pii: 10.1038/s41409-021-01551.
    PubMed     Abstract available


    November 2021
  307. FURTADO VF, Brauneis D, Weinberg J, Elhassan N, et al
    Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis.
    Bone Marrow Transplant. 2021 Nov 29. pii: 10.1038/s41409-021-01535.
    PubMed    


  308. LEAL CTS, Costa LJM, Pereira J, Duarte FB, et al
    Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients.
    Bone Marrow Transplant. 2021 Nov 29. pii: 10.1038/s41409-021-01531.
    PubMed    


  309. IMAHASHI N, Terakura S, Kondo E, Kato K, et al
    Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.
    Bone Marrow Transplant. 2021 Nov 24. pii: 10.1038/s41409-021-01525.
    PubMed     Abstract available


  310. SHUMILOV E, Shakhanova I, Flach J, Schmidt N, et al
    Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation.
    Bone Marrow Transplant. 2021 Nov 13. pii: 10.1038/s41409-021-01521.
    PubMed     Abstract available


  311. HOLIG K, Schmidt H, Hutter G, Kramer M, et al
    Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.
    Bone Marrow Transplant. 2021 Nov 12. pii: 10.1038/s41409-021-01523.
    PubMed    


  312. SCHETELIG J, Chevallier P, van Gelder M, Hoek J, et al
    Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
    Bone Marrow Transplant. 2021 Nov 12. pii: 10.1038/s41409-021-01516.
    PubMed    


  313. OTTH M, Yammine S, Usemann J, Latzin P, et al
    Longitudinal lung function in childhood cancer survivors after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2021 Nov 8. pii: 10.1038/s41409-021-01509.
    PubMed     Abstract available


  314. SCHMID C, Labopin M, Schaap N, Veelken H, et al
    Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia.
    Bone Marrow Transplant. 2021 Nov 8. pii: 10.1038/s41409-021-01515.
    PubMed     Abstract available


  315. ALZAHRANI M, Damlaj M, Essa M, Alahmari B, et al
    HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: age is not a barrier to successful outcome.
    Bone Marrow Transplant. 2021 Nov 6. pii: 10.1038/s41409-021-01513.
    PubMed    


  316. GARNICA M, Dalcolmo S, Gaio B, de Almeida AR, et al
    Pre-engraftment Cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation and its impact on engraftment.
    Bone Marrow Transplant. 2021 Nov 1. pii: 10.1038/s41409-021-01520.
    PubMed    


  317. KASIKIS S, Baez J, Gandhi I, Grupp S, et al
    Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers.
    Bone Marrow Transplant. 2021;56:2869-2870.
    PubMed    


    October 2021
  318. MARTINO R, Garcia-Cadenas I, Esquirol A
    Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation.
    Bone Marrow Transplant. 2021 Oct 28. pii: 10.1038/s41409-021-01507.
    PubMed    


  319. MIKULSKA M, Penack O, Wendel L, Knelange N, et al
    HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party.
    Bone Marrow Transplant. 2021 Oct 23. pii: 10.1038/s41409-021-01497.
    PubMed     Abstract available


  320. MARTINO M, Pitino A, Gori M, Viens P, et al
    Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study.
    Bone Marrow Transplant. 2021 Oct 23. pii: 10.1038/s41409-021-01503.
    PubMed    


  321. TIEN FM, Tsai CH, Huang SC, Liu JH, et al
    Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission.
    Bone Marrow Transplant. 2021 Oct 20. pii: 10.1038/s41409-021-01454.
    PubMed     Abstract available


  322. WANG X, Yu U, Yang C, Wang C, et al
    Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2021 Oct 20. pii: 10.1038/s41409-021-01499.
    PubMed    


  323. SMITH PJ, Lew M, Lowder Y, Romero K, et al
    Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2021 Oct 19. pii: 10.1038/s41409-021-01470.
    PubMed     Abstract available


  324. VO P, Onstad L, Flowers ME, Storb R, et al
    Cancers after HLA-matched related bone marrow transplantation for aplastic anemia.
    Bone Marrow Transplant. 2021 Oct 16. pii: 10.1038/s41409-021-01498.
    PubMed     Abstract available


  325. CARTER M, Taniguchi M, Yang D, Arslan S, et al
    Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.
    Bone Marrow Transplant. 2021 Oct 11. pii: 10.1038/s41409-021-01494.
    PubMed    


  326. SALVINI M, Maggi F, Damonte C, Mortara L, et al
    Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation.
    Bone Marrow Transplant. 2021 Oct 11. pii: 10.1038/s41409-021-01487.
    PubMed    


  327. KOBAYASHI S, Kanda Y, Konuma T, Inamoto Y, et al
    Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.
    Bone Marrow Transplant. 2021 Oct 8. pii: 10.1038/s41409-021-01485.
    PubMed     Abstract available


  328. SELLNER L, Schetelig J, Koster L, Choi G, et al
    Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey.
    Bone Marrow Transplant. 2021 Oct 7. pii: 10.1038/s41409-021-01490.
    PubMed    


  329. SAVOIA C, McKeough N, Hickey B, Cochrane T, et al
    Comparison of a therapeutic platelet transfusion strategy to a prophylactic platelet transfusion strategy in autologous stem cell transplant (ASCT), a single centre experience.
    Bone Marrow Transplant. 2021 Oct 6. pii: 10.1038/s41409-021-01482.
    PubMed    


  330. MILLARD T, Sammour F, Anthias C, Easdale S, et al
    Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?
    Bone Marrow Transplant. 2021 Oct 5. pii: 10.1038/s41409-021-01484.
    PubMed    


  331. POIRE X, Graux C, Ory A, Herman J, et al
    Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective s
    Bone Marrow Transplant. 2021 Oct 5. pii: 10.1038/s41409-021-01464.
    PubMed    


  332. PERRUCCIO K, Menconi M, Galaverna F, Pagliara D, et al
    Safety and efficacy of brincidofovir for Adenovirus infection in children receiving allogeneic stem cell transplantation: an AIEOP retrospective analyses.
    Bone Marrow Transplant. 2021 Oct 4. pii: 10.1038/s41409-021-01285.
    PubMed    


  333. NAKAMURA ZM, Heiling HM, Park EM, Deal AM, et al
    Impact of patient and clinical characteristics on cognitive changes after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2021 Oct 2. pii: 10.1038/s41409-021-01481.
    PubMed    


    September 2021
  334. MAMEZ AC, Pradier A, Giannotti F, Petitpas A, et al
    Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2021 Sep 28. pii: 10.1038/s41409-021-01466.
    PubMed    


  335. PERIC Z, Peczynski C, Polge E, Kroger N, et al
    Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT.
    Bone Marrow Transplant. 2021 Sep 24. pii: 10.1038/s41409-021-01458.
    PubMed    


  336. YOKOYAMA H, Hirayama M, Takahashi Y, Uchida N, et al
    Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation.
    Bone Marrow Transplant. 2021 Sep 24. pii: 10.1038/s41409-021-01469.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stem Cell Research is free of charge.